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SIGNIFICANCE
This study analysed the prescription of systemic treatment 
by dermatologists in patients with chronic itch. Overall, 
6 out of 10 dermatologists prescribed antidepressants or 
gaba pentinoids, of which, antidepressants were prescribed 
most frequently. Reasons not to prescribe systemic treat­
ment included lack of knowledge or experience, risk of side­ 
effects, and lack of available evidence. Only a minority of 
the clinicians surveyed felt comfortable prescribing these 
drugs; therefore, we recommend more education on ef­
fective and safe dosing.
Treatment of chronic pruritus can be a challenge for 
clinicians. Several systemic treatments have been 
suggested to reduce itch, such as gabapentinoids and 
antidepressants. The aim of this study was to assess 
the current practice of dermatologists regarding sys-
temic treatment in patients with chronic pruritus, and 
to identify possible barriers in the prescription of these 
treatments. An online survey was sent to all derma-
tologists and dermatology residents in the Nether-
lands between July 2017 and April 2018. A total of 193 
physi cians completed the questionnaire (response rate 
27.0%). Overall, 61.7% prescribed gabapentinoids or 
antidepressants in patients with chronic pruritus. Ami-
triptyline was prescribed most frequently, followed by 
gabapentin, doxepin and mirtazapine. Reasons not to 
prescribe systemic treatment included lack of know-
ledge or experience, risk of side-effects, and lack of 
available evidence. As only a minority of respondents 
felt comfortable prescribing these drugs, more educa-
tion on effective and safe dosing is needed.
Key words: pruritus; therapeutics; gabapentin; antidepressive 
agents; survey.
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Itch is one of the most common symptoms presented in daily dermatological practice, with an estimated 
point prevalence of 36.2% (1–3). Chronic pruritus (CP) 
(itch present for a minimum of 6 weeks) can be caused 
by several dermatological, systemic, neurological and 
psychiatric disorders (2, 4). CP is associated with a 
reduced quality of life, including impact on mood, con-
centration and sleep, and a higher risk of anxiety and 
depression (5–8).
Several systemic treatment options have been sug-
gested for patients with CP (2, 9–11). For example ga-
bapentinoids, such as gabapentin and pregabalin, were 
used in patients with uremic pruritus and neurogenic itch 
(12–20). In addition, treatment with oral antidepressants, 
such as mirtazapine, paroxetine and sertraline, have been 
recommended in patients with pruritus unresponsive 
to conventional treatment options, and particularly in 
patients with uraemic pruritus, cholestatic pruritus or 
paraneoplastic pruritus (21–28). Other systemic treat-
ment options include opioid receptor agonists and anta-
gonists, thalidomide and neurokinin 1 receptor (NKR1) 
antagonists (29–36).
Due to its heterogeneity and difficult to establish 
underlying origin, treatment of CP remains a challenge 
for clinicians (37, 38). If systemic treatment is initiated, 
side-effects can complicate therapeutic attempts, especi-
ally in elderly patients. In addition, dermatologists might 
not feel comfortable prescribing psychotropic medication 
(39). Data on the use of systemic treatments for CP by 
clinicians in daily practice is currently scarce. 
The aim of this study was to provide more insight into 
the current practice of dermatologists regarding systemic 
treatment in patients with CP, including identification of 
the treatments used, clinicians’ experiences on reducing 
itch after initiation of systemic treatment, and possible 
barriers to prescription of systemic treatment. 
METHODS
An anonymous web-based questionnaire was sent by e-mail to all 
members of the Dutch Society of Dermatology and Venereology 
(NVDV) between July 2017 and April 2018. It was first piloted 
to dermatologists (n = 3) and dermatology residents (n = 6) in June 
2017 at the Radboud University Medical Center, Nijmegen, the 
Netherlands, resulting in the adaptation of a few questions and 
instructions to avoid ambiguity. The final questionnaire consisted 
of 19 questions, including multiple-choice questions, 5-point 
Likert scale questions and open-ended questions. Participants 
were asked about demographic and professional data, prevalence 
of CP in their clinical practice, use of antiepileptics and antide-
pressants in treatment of CP, their level of comfort in prescribing 
these pharmaceuticals and other systemic treatment options used 
in treatment of CP. In this survey, CP was defined as itch present 
for a minimum of 6 weeks due to both dermatological and non-
dermatological conditions. Study data were collected and managed 
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by Qualtrics web-based survey software (Provo, UT, USA). The 
entire survey is available in Table SI1. 
Data of respondents were displayed as means and standard 
deviations (SD) for continuous variables, and numbers and per-
centages for categorical variables (n (%)). Age, sex, profession and 
practice setting of the respondent population were compared with 
the target population to test for selection bias. Subgroup analyses 
were conducted to compare the influence of physician subgroup, 
years of clinical experience and practice setting on the prescription 
of systemic treatments using independent χ2 tests. p < 0.05 was 
considered statistically significant. All statistical analyses were per-
formed with SPSS, version 22.0 (IBM SPSS Inc, Chicago, USA). 
RESULTS
A total of 193 members responded (response rate 27.0%), 
including 155 (80.3%) dermatologists and 38 (19.7%) 
dermatology residents (Table I). The mean ± SD age of all 
respondents (67.9% women) was 42.7 ± 0.6 years. Most 
respondents practiced in a general hospital (60.6%) or 
academic hospital (31.1%). A comparison of sex, age, 
profession and practice setting between the respondent 
population and target population showed no significant 
differences (data available on request). 
Prevalence of chronic pruritus
Respondents were asked to estimate the number of 
patients seen with CP that could not be resolved by 
treatment of an underlying cause or by conventional 
treatment options (e.g. topical treatments or oral anti-
histamines), and therefore had a possible indication for 
systemic treat ment. Most respondents estimated that they 
saw at least one patient in the described population per 
week (33.2%) or per month (33.7%), followed by one 
patient per 3 months (13%) or even one patient per day 
(9.8%) (Table II). 
Use of gabapentin and pregabalin 
Overall, 74 (38.3%) respondents prescribed gabapenti-
noids for patients with CP (Table II), of whom 47 (64.4%) 
prescribed gabapentin, 10 (13.7%) prescribed pregabalin 
and 16 (21.9%) prescribed both. When these respondents 
were asked about the efficacy of these treatments on 
reducing itch using a 5-point Likert scale (ranging from 
very poor to very good), the majority reported a fair 
(gabapentin 61.9%; pregabalin 66.7%) or good (gaba-
pentin 25.4%; pregabalin 22.2%) treatment effect (Table 
III). Significantly more respondents who are currently 
working in an academic hospital (66.0%; p = 0.000) pres-
cribed gabapentin or pregabalin compared with respon-
dents working in general hospitals (26.7%) or private 
practices (19.0%) (Table SII1). In addition, significant 
differences were found according to profession (derma-
tologist 32.9%; dermatology resident 60.5%; p = 0.002) 
and clinical experience (0–10 years 51.0%; 10–20 years 
24.0%; > 20 years 27.7%; p = 0.001). When respondents 
not prescribing gabapentin or pregabalin (n = 119; 61.7%) 
were asked to explain why they did not prescribe these 
pharmaceuticals, the majority stated they did not have 
Table I. Demographics of survey respondents (n = 193)
Characteristics of respondents
Sex, n (%)
  Male
  Female
62 (32.1)
131 (67.9)
Age, years (n = 190) mean ± SD 42.7 ± 10.6
Profession, n (%)
  Dermatologist
  Dermatology resident
155 (80.3)
38 (19.7)
Practice settinga, n (%)
  Academic hospital
  General hospital
  Private practice
  Other
60 (31.1)
117 (60.6)
31 (16.1)
4 (2.1)
Years of clinical experience, n (%) 
  0–10 years
  10–20 years 
  > 20 years 
96 (49.7)
50 (25.9)
47 (24.4)
aTotal number of respondents does not equal sum of respondents reporting 
different practice settings because more than one setting can be reported by the 
same respondent. 
SD: standard deviation.
Table II. Prevalence of chronic pruritus in daily clinical practice, 
prescription of antiepileptic treatment in patients with chronic 
pruritus (CP) and prescription of antidepressants in patients with CP
Indication of patients seen in daily clinical practice with CP and an indication for 
systemic treatment estimated by survey respondents (n=193), n (%)
Every day
Every week
Every month
Every 3 months
Every 6 months
Every year
Less than once per year
19 (9.8)
64 (33.2)
65 (33.7)
25 (13.0)
11 (5.7)
  6 (3.1)
  3 (1.6)
Prescription of antiepileptic treatment in patients with CP, n (%)
Prescription of antiepileptic treatment for CP (n = 193)
  Yes
  No
  74 (38.3)
119 (61.7)
Specification of antiepileptic treatment prescribed for CPa (n = 74)
  Gabapentin
  Pregabalin
63 (85.1)
26 (35.1)
Reasons not to prescribe antiepileptic treatment for patients with CPa (n = 119)
  Not enough knowledge or experience
  Side­effects
  Not enough evidence
  Interactions
  Other
103 (86.6)
  16 (13.4)
  11 (9.2)
    1 (0.8)
  12 (10.1)
Prescription of antidepressants in patients with CP, n (%)
Prescription of antidepressants for CP (n = 192)
  Yes
  No
101 (52.6)
  91 (47.4)
Specification of antidepressants prescribed for CPa (n = 101)
  Amitriptyline
  Doxepin
  Mirtazapine
  Paroxetine
  Nortriptyline
  Fluoxetine
  Sertraline
82 (81.2)
30 (29.7)
13 (12.9)
12 (11.9)
  7 (6.9)
  2 (2.0)
  2 (2.0)
Reasons not to prescribe antidepressants for patients with CPa (n = 91)
  Not enough knowledge or experience
  Side­effects
  Not enough evidence
  Interactions
  Other
80 (87.9)
15 (16.5)
11 (12.1)
  1 (1.1)
  5 (5.5)
aTotal number of respondents does not equal sum of patients reporting different 
outcomes because more than one can be reported by the same respondent.1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555­3101
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enough knowledge or experience (86.5%), followed by 
risk of side-effects of gabapentinoids (13.4%) and lack 
of available evidence on efficacy of antiepileptic treat-
ment (9.2%) (Table II). Two respondents stated that they 
had not heard of the option of gabapentin or pregabalin 
treatment for CP. 
Use of antidepressants
Over half of those surveyed (52.6%) prescribed oral anti-
depressants for treatment of CP (Table II). The majority 
of these respondents prescribed amitriptyline (81.2%), 
followed by doxepin (29.7%), mirtazapine (12.9%), 
paroxetine (11.9%) and nortriptyline (6.9%). Only 2 
respondents prescribed fluoxetine (2.0%) or sertraline 
(2.0%). The treatment effect of these drugs was mostly 
rated as ‘fair’ or ‘good’ (Table III). One respondent even 
reported a ‘very good’ treatment effect after initiation of 
mirtazapine. No significant differences in prescription 
of antidepressants were found with respect to profes-
sion, years of clinical experience or practice setting 
(Table SII1). Respondents not prescribing antidepressants 
(n = 91; 47.4%) stated they had not enough knowledge or 
experience (87.9%); or were worried about side-effects 
(16.5%) and lack of available evidence (12.1%) (Table 
II). 
Being comfortable about prescribing antiepileptic and 
antidepressant drugs
When participants were asked if they were comfortable 
about prescribing gabapentinoids, the majority disa-
greed (32.3%), or strongly disagreed (20.3%) (Table 
IV). When these outcomes were specified for respon-
dents prescribing gabapentin or pregabalin, more 
respondents reported feeling comfortable (30.1% vs. 
11.8%; p = 0.000). The same was true for prescription 
of antidepressants, as the majority of respondents also 
disagreed about feeling comfortable prescribing these 
drugs (34.2%), and more respondents felt comfortable if 
they were actually prescribing these treatments (27.7% 
vs. 11.0%; p = 0.000). 
Other treatment options 
When asked about other treatment options used by re-
spondents in daily clinical practice for the treatment of 
CP, the majority of respondents reported oral immuno-
suppressants, such as methotrexate or cyclosporine A, 
and opioid antagonists, such as naltrexone. Other sug-
gestions were haloperidol, ondansetron and thalidomide. 
DISCUSSION
This survey was conducted to investigate the current 
practice of dermatologists and dermatology residents 
in the Netherlands regarding systemic treatment in pa-
tients with CP. More than 40% of respondents reported 
having seen patients with CP and a possible indication 
for systemic treatment at least once per day or once per 
week, and another 30% reported seeing such patients at 
least once every month. As this is even more than the 
estimated point prevalence of CP described earlier in a 
cross-sectional study in dermatological practice (1), a 
large group of patients demands an effective and safe 
treatment for their symptoms. 
Table III. Respondent experiences on reducing itch after initiation 
of antiepileptic medication (n = 74) or antidepressants (n = 101) 
using a 5-point Likert scale
Very 
poor
n (%)
Poor
n (%)
Fair
n (%)
Good
n (%)
Very 
good
n (%)
Gabapentin (n = 63) 1 (1.6) 4 (6.3) 39 (61.9) 16 (25.4) 3 (4.8)
Pregabalin (n = 26) 0 3 (11.5) 17 (65.4)   6 (23.1) 0
Amitriptyline (n = 82) 0 5 (6.1) 54 (65.9) 23 (28.0) 0
Doxepin (n = 30) 0 2 (6.7) 14 (46.7) 14 (46.7) 0
Mirtazapine (n = 13) 0 0 11 (84.6) 1 (7.7) 1 (7.7)
Paroxetine (n = 12) 1 (8.3) 0 9 (75.0) 2 (16.7) 0
Nortriptyline (n = 7) 0 0 4 (57.1) 3 (42.9) 0
Fluoxetine (n = 2) 0 0 1 (50.0) 1 (50.0) 0
Sertraline (n = 2) 0 0 2 (100.0) 0 0
Table IV. Respondents feeling comfortable prescribing antiepileptic treatment and antidepressants for the treatment of itch
Total respondents
(n = 192)
n (%)
Prescribing antiepileptic 
treatment (n = 73)
n (%)
Not prescribing antiepileptic 
treatment (n = 119)
n (%) p­value
’I feel comfortable prescribing antiepileptic treatment’ 0.000
    Strongly disagree 39 (20.3)   2 (2.7) 37 (31.1)
    Disagree 62 (32.3) 12 (16.4) 50 (42.0)
    Neither agree or disagree 44 (22.8) 35 (47.9)   9 (7.6)
    Agree 36 (18.7) 22 (30.1) 14 (11.8)
    Strongly agree 11 (5.7)   2 (2.7)   9 (7.6)
Prescribing antidepressants 
(n = 101) 
n (%)
Not prescribing 
antidepressants (n = 91) 
n (%)
’I feel comfortable prescribing antidepressants’ 0.000
    Strongly disagree 24 (12.4)   2 (2.0) 22 (24.2)
    Disagree 66 (34.2) 20 (19.8) 46 (50.5)
    Neither agree or disagree 56 (29.0) 48 (47.5)   8 (8.8)
    Agree 38 (19.7) 28 (27.7) 10 (11.0)
    Strongly agree   8 (4.1)   3 (3.0)   5 (5.5)
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In our study, more than half of the physicians surveyed 
(52.6%) have prescribed antidepressants in patients with 
CP. The most commonly prescribed antidepressant was 
amitriptyline (81.2%). However, evidence for the use 
of amitriptyline in the treatment of CP is limited, as it 
was described in only one observational study, 2 case 
series and 3 case reports, mainly describing patients with 
pruritus of neuropathic origin (e.g. brachioradial pruritus 
or notalgia paraesthetica) (40–45). The other frequently 
prescribed antidepressants, doxepin (29.7%), mirtazapine 
(12.9%) and paroxetine (11.9%), have been described 
more frequently, mostly for paraneoplastic pruritus, 
uremic pruritus or pruritus of unknown origin (21, 23, 
24, 28, 46–50), and were recommended in guidelines 
for various forms of CP not responsive to conventional 
treatment options (2, 9, 51). This discrepancy could be 
explained as amitriptyline is an established pharmaco-
logical intervention for neuropathic pain (52), and is 
therefore well known by most dermatologists.
According to the respondents in our survey, gabapen-
tinoids are prescribed less frequently in daily practice 
compared with antidepressants (38.3% vs. 52.6%). Of 
these 2 treatments, gabapentin is prescribed more often 
compared with pregabalin (65.0% vs. 35.0%), probably 
as pregabalin is a relatively new drug with fewer studies 
examining its use in patients with CP (10). In addition, 
evidence comparing the efficacy of gabapentin and 
pregabalin is limited, with only one open-label trial in 
haemodialysis patients with neuropathic pruritus (n = 40), 
showing no significant difference between the 2 phar-
maceuticals (53). 
Almost all respondents not prescribing antiepileptics or 
antidepressants (86.5% and 87.9%, respectively), stated 
they had limited knowledge or experience to initiate these 
treatments. In addition, 2 respondents stated that they 
never heard of the option of gabapentin or pregabalin 
treatment in patients with CP. Lack of experience and 
knowledge was also shown by the low rates of respon-
dents feeling comfortable prescribing these drugs. For 
example, more than half of respondents prescribed anti-
depressants, with only 23.8% feeling comfortable or very 
comfortable prescribing them. These results are similar 
to a previous survey evaluating the use of psychotropic 
treatment among dermatologists (n = 59), showing that 
only a few dermatologists felt comfortable (11%) or 
very comfortable (3%) prescribing antidepressants for 
psychocutaneous disorders (39). Interestingly, in the 
same population far more dermatologists felt comfortable 
(66%) or very comfortable (18%) starting treatment for 
neuropathic pain, including gabapentin and pregabalin. 
It is important to acknowledge dermatologists’ lack of 
knowledge and experience on prescription of these drugs, 
especially as not all patients can be seen in specialized 
centres due to the high prevalence of this symptom. Use 
of guidelines, education on effective and safe dosing, and 
close cooperation with specialized centres can be helpful 
to improve care of CP. 
In a recent survey conducted in Germany, patients with 
CP reported finding a clear diagnosis and therapy, being 
free of itch and having confidence in the therapy as their 
most important treatment goals (54). However, effective 
treatment of CP remains a challenge for clinicians, often 
using gabapentinoids and antidepressants as a last resort 
(37, 38). As these pharmaceuticals might have substantial 
side-effects, especially in geriatric patients or patients 
with multiple comorbidities or concomitant medications, 
and are not registered for treatment of CP, there is still an 
unmet need for an effective and safe treatment (10, 11).
A limitation of our survey is the response rate of 
approximately 30%, and therefore a risk of selection 
bias. However, no significant differences in age, sex, 
profession and practice setting were found between our 
response population and the target population. 
In conclusion, over half of respondents of our survey 
prescribed antidepressants for treatment of pruritus. Even 
though evidence is scarce, amitriptyline was prescribed 
most often, followed by mirtazapine, doxepin and pa-
roxetine. Compared with antidepressants, gabapentin 
and pregabalin were prescribed less frequently. A mi-
nority of respondents felt comfortable prescribing these 
treatments, and a lack of knowledge and experience was 
considered the main reason not to prescribe antiepileptic 
of antidepressant treatment. Therefore, we recommend 
more education on effective and safe dosing.
The authors have no conflicts of interest to declare.
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